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Abstract
Background: Among the possible candidate genes for atherosclerosis experimental data point
towards the longevity gene p66Shc. The p66Shc gene determines an increase of intracellular reactive
oxygen species (ROS), affecting the rate of oxidative damage to nucleic acids. Knock-out p66Shc-/-
mice show reduction of systemic oxidative stress, as well as of plasma LDL oxidation, and reduced
atherogenic lesions. Thus, p66Shc may play a pivotal role in controlling oxidative stress and vascular
dysfunction in vivo.
Methods: We searched for sequence variations in the p66Shc specific region of the Shc gene and
its upstream promoter by PCR-SSCP in a selected group of early onset coronary artery disease
(CAD) subjects (n. 78, mean age 48.5 ± 6 years) and in 93 long-living control subjects (mean age
89 ± 6 years).
Results: The analysis revealed two variant bands. Sequencing of these variants showed two SNPs:
-354T>C in the regulatory region of p66Shc locus and 92C>T in the p66 specific region (CH2). Both
these variants have never been described before. The first substitution partially modifies the binding
consensus sequence of the Sp1 transcription factor, and was detected only in two heterozygous
carriers (1 CAD subjects and 1 control subject). The 92C>T substitution in the CH2 region
consists in an amino acid substitution at codon 31 (proline to leucine, P31L), and was detected in
heterozygous status only in one CAD subject. No subjects homozygous for the two newly
described SNPs were found.
Conclusion: Only two sequence variations in the p66Shc gene were observed in a total of 171
subjects, and only in heterozygotes. Our observations, in accordance to other studies, suggest that
important variations in the p66Shc gene may be extremely rare and probably this gene is not
involved in the genetic susceptibility to CAD.
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Background
Increasing evidence indicates that reactive oxygen species
(ROS) may participate in the pathogenesis of various dis-
eases, including cardiovascular disorders. Support to this
comes from the experimental demonstration that vessel
walls of patients with atherosclerotic risk factors are char-
acterized by a significant increase in vascular ROS produc-
tion [1].
It has been reported that the p66Shc  longevity gene
increases intracellular reactive oxygen species (ROS),
thereby affecting the rate of oxidative damage to nucleic
acids [2]. The human Shc locus (Src homologous and col-
lagen) encodes three proteins with relative molecular
masses of 46K (p46Shc), 52K (p52Shc) and 66K (p66Shc).
All three proteins share a Src-homology2 (SH2) domain,
a collagen-homology (CH1) region and a phosphotyro-
sine-binding (PTB) domain. The p66Shc protein contains a
unique amino terminal region (CH2) [3]. p46Shc, p52Shc
and p66Shc are adaptor proteins in the insulin-signalling
pathway, but their downstream effects differ: p46Shc and
p52Shc are tyrosine-phosphorylated by a variety of growth
factors, and are associated with MAPK signalling; p66Shc
also undergoes tyrosine phosphorylation in response to
extracellular signals but is involved in signal transduction
pathways that inhibits the activation of c-fos promoter
[4]. C-fos is transcriptionally activated in response to envi-
ronmental stresses such as ultraviolet light (UV) or H2O2.
Thus, there is in vitro evidence that p66Shc is part of a com-
plex transduction pathway that controls oxidative stress
[4].
Knock out mice for the p66Shc gene locus show a higher
resistance to oxidative stress and extended life span (up to
30%) [3]. Moreover, p66Shc-/- cells show a reduced oxida-
tive stress-induced apoptosis, which is restored by p66Shc
over expression [3].
Also, the role of p66Shc in muscle damage that follows
acute hindlimb ischemia has been investigated. Results
showed that p66Shc-/- mice were resistant to tissue damage
induced by ischemia and ischemia/reperfusion secondary
to ROS generation, demonstrating that p66Shc plays a cru-
cial role in the cell death pathways activated by acute
ischemia [5].
Further studies using p66Shc-/- mice showed a significant
reduction of systemic oxidative stress, plasma LDL oxida-
tion and early atherosclerotic lesions when mice were fed
a high-fat diet [6].
p66Shc expression is tissue specific [7] and it is regulated by
epigenetic modifications, namely histone deacetylation
and cytosine methylation. In this regard, it has been
reported that histone deacetylase inhibitors and demeth-
ylating agents restore p66Shc expression in human periph-
eral blood lymphocytes (PBL) that normally do not
express this isoform [8].
More recent studies have observed that absence of p66Shc
expression might contribute to the protection of the heart
from the deleterious effects of elevated Angiotensis II lev-
els [9]. Furthermore, it was reported that inactivation of
the p66Shc  gene protects against age-dependent ROS-
mediated endothelial dysfunction [10] in p66Shc KO mice.
It appears therefore that p66Shc may play a pivotal role in
controlling oxidative stress and vascular dysfunction in
vivo, possibly regulating the evolution of the atheroscle-
rotic process. Based on this background, we investigated
the p66Shc specific region of the Shc gene and its upstream
promoter for variations in a selected group of subjects
with early-onset coronary artery disease (CAD).
Results
The possible effect of p66Shc longevity gene mutations on
CAD would probably determine an early onset of the dis-
ease, and assuming that a genetic effect might be more evi-
dent in younger patients, we choose to select subjects with
age of diagnosis of CAD <55 years. This age limit was
based on the incidence curves of CAD and the estimates of
genetic effect at various ages [11,12]. As controls we stud-
ied 93 unrelated long-living subjects (mean age 89 ± 6
years) randomly selected from a population of individu-
als screened for CAD risk factors.
The human Shc locus encodes three proteins (p46, p52
and p66) by using two alternative promoters that synthe-
size two mRNAs coding for p46/p52 and for p66 [8]. The
p66Shc promoter, positioned in the first intron of the Shc
locus, contains a relative high frequency of CpG dinucle-
otides whose methylation regulates the transcriptional
activity of p66Shc promoter [8]. Considering the recent
observations that alterations in expression of p66Shc gene
might be one possible cause in determining life span and
in controlling oxidative stress, we hypothesised that
sequence variations in p66Shc promoter may contribute to
both aging and early atherogenesis. PCR-SSCP analysis of
the p66 specific region of the Shc locus and the p66Shc pro-
moter (from nucleotide -637) revealed two variant bands
(Figure 1). Sequencing of these variants showed two
SNPs: -354T>C in the regulatory region of p66Shc locus
and 92C>T in the p66 specific region (CH2). The first sub-
stitution partially modifies the binding consensus
sequence of the Sp1 transcription factor, and was detected
only in two heterozygous carriers (1 CAD subject and 1
control subject). The 92C>T substitution in the CH2
region consists in an amino acid substitution at codon 31
in which proline is substituted with leucine (P31L), and
was detected in heterozygous status only in one CAD sub-BMC Genetics 2006, 7:14 http://www.biomedcentral.com/1471-2156/7/14
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ject. No subjects homozygous for the two newly described
SNPs were found. One family member of the subject car-
rying the P31L mutation, also affected by early-onset CAD
(the brother, age 37 years), was screened for these new
polymorphisms, but no SNPs were detected.
Discussion
We screened for new DNA polymorphisms the p66 spe-
cific region of the Shc locus (CH2) and the p66Shc pro-
moter. We identified by PCR-SSCP assay of 1167 base
pairs in 4 amplified segments two segregating sites in 2
Mutation detection with SSCP and sequence electropherograms of p66Shc Figure 1
Mutation detection with SSCP and sequence electropherograms of p66Shc. PCR-SSCP and sequence analysis of the 
regulatory region of p66Shc locus (A) and of the p66Shc specific region CH2 (B). In the sequence electropherograms, arrows 
indicate the nucleotide substitution in heterozygous subjects as shown by the presence of the 2 superimposed peaks repre-
senting the normal and abnormal base. A) SSCP analysis of the 5' regulatory region of p66 locus (T/T subjects with wild-type 
sequence, T/C subjects heterozygous for the variant). B) SSCP analysis of the CH2 region: the 92C>T substitution consisted in 
an amino acid substitution P31L (C/C subjects with wild-type sequence, C/T subject heterozygous for the variant).BMC Genetics 2006, 7:14 http://www.biomedcentral.com/1471-2156/7/14
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out of the 342 chromosomes examined. The two novel
variants (-354T>C and 92C>T) were very rare in both pop-
ulations of CAD and elderly subjects. Furthermore, no
subject homozygous for the two SNPs was found.
Our observations agree with a previous study performed
in a sample of extreme survivors of the Leiden 85-plus
Study, where no sequence variations in the p66 specific
region of the Shc gene were found [13].
The Shc gene contains one known non-synonymous pol-
ymorphism located in the CH1 domain which corre-
sponds to Met300Val in the p52 isoform and to Met410Val
in the p66 isoform [13]. No association of the Met300Val
(the p52 isoform) variation was found with birth weight
and length, impaired insulin secretion, insulin resistance
and type 2 Diabetes Mellitus in a cohort of 360 young
healthy Danish Caucasian subjects [14]. In a more recent
study the Met410Val variant (the p66 isoform) was tested
for association with longevity using a prospective follow-
up design in two independent cohorts of 730 and 563
subjects aged 85 and over [13]. Mooijaart and co-workers
observed a small increase in Val allele with increasing age
of death and a decreased mortality risk of Met/Val carriers
compared to Met/Met carriers; however no statistical sig-
nificance was reached in the two different analyses [13].
These results suggest a possible beneficial effect of the
Valine allele on longevity, but no subject homozygous for
valine was found and the frequency of this allele was very
low in this cohort. To date, no functional studies on the
Met/Val variant of the p66Shc isoform have been per-
formed.
Finally, this Met/Val amino acid variant is present in all 3
isoform of the Shc gene, thus suggesting that this poly-
morphism is unlikely to specifically affect the function of
p66Shc and not of p46Shc and p52Shc. For all these reasons
we did not study the Met/Val variant in our cohorts, since
we were looking for variants that would affect particularly
the p66Shc gene.
Conclusion
Longevity is a complex trait, resulting from the interaction
between multiple genetic and environmental factors.
Before our, several studies in long-lived subjects have
highlighted the role of biological factors as determinant of
'successful ageing'. For example associations between suc-
cessful ageing and paraoxonase 1 (PON1) and interleukin
10 (IL-10) gene polymorphisms have been reported in
centenarian [15-17]. However, confirmatory data is
needed, and probably several other genetic factors are
involved.
In our study we had hypothesised that the p66Shc gene
may play a pivotal role in controlling oxidative stress and
vascular dysfunction in vivo, possibly regulating the evolu-
tion of the atherosclerotic process. In view of its associa-
tion with CAD in animal models, we assumed that
sequence variations would be less frequent in elderly sur-
vivors compared to younger CAD subjects.
We screened for new DNA polymorphisms the p66 spe-
cific region of the Shc locus (CH2) and the p66Shc pro-
moter and identified two very rare novel variants with no
subject homozygous for these SNPs.
Our observations agree with a previous study where no
sequence variations in the p66 specific region of the Shc
gene were found [13]. In the rest of the Shc gene, only one
nucleotide substitution (Met/Val) has been reported,
located in the CH1 domain and common to all three iso-
forms of the Shc gene [13,14]. These observations,
together with our data, suggest that important variations
in the Shc gene may not be tolerated and that evolution
might have selected against their occurrence, and it
appears that the role of p66Shc gene in mammalian lon-
gevity is probably more complex than previously thought.
Methods
Subjects selection
The p66 specific region of the Shc locus and the p66Shc
promoter were screened for new sequence variants in 78
subjects with early-onset coronary disease (<55 years,
mean age 48.5 ± 6 year) recruited among subjects under-
going coronary angioplasty or presenting with clear evi-
dence of CAD (previous diagnosis of MI, or one or more
stenoses greater than 50% in at least one major coronary
artery after coronary catheterisation and clinical symp-
toms of angina). Diagnosis of MI was based on typical
electrocardiographic changes and elevation of at least two
Table 1: Primers for PCR-SSCP analysis of p66Shc gene
Amplicon Product size (bp) Forward primer (5'-) Reverse primer (5'-)
CH2 352 gcccctctttcacctcaact atgtcctggaggaggggtag
Promoter-1 238 cagagaagaggctccacgtt ggggcaggagatccatagtt
Promoter-2 247 cccacccccactttacttct aacgtggagcctcctctctg
Promoter-3 330 aggacaggaagggaaatgct agtgctgactcacaggctca
Forward and reverse primer sequences are all 5'. Promoter-1 fragment starts at nucleotide -222 from start codon of exon1; Promoter-2 fragment 
starts at nucleotide -449 from start codon of exon1; Promoter-3 fragment starts at nucleotide -637 from start codon of exon1 of p66Shc gene.BMC Genetics 2006, 7:14 http://www.biomedcentral.com/1471-2156/7/14
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enzymes, and was confirmed by the presence of wall
motion abnormalities in left ventriculography.
Control subjects were 93 unrelated long-living subjects
(mean age 89 ± 6years) randomly selected from a popula-
tion of individuals screened for CAD risk factors. Exclu-
sion criteria were: 1) the presence of CAD 2) the presence
of type 2 diabetes. CAD was excluded by use of the Rose
questionnaire [18] and ECG (Minnesota coding). A com-
plete medical history in all subjects was obtained by ques-
tionnaire. History taking included questions about
smoking habits, history of hypertension and type 2 diabe-
tes and current medications. Diagnosis of type 2 diabetes
was based on history of hypoglycaemic treatment and/or
confirmed fasting blood glucose >126 mg/dl (7.0 mmol/
L). All Caucasian subjects were recruited in the Centre-
West Coast of Italy, most from Rome and its surrounding
towns. All subjects gave their written informed consent to
their participation to the study. The study was approved
by the University of Rome "La Sapienza" Ethical Commit-
tee.
Molecular genetic screening
Sequence variants of the p66Shc gene were analyzed with
the PCR-SSCP technique as previously described [19].
Briefly, primers were designed to include the specific
amino terminal region (CH2) of the p66 protein and the
p66Shc promoter in order to evaluate possible mutations
and to yield PCR fragments of 200–350 bp (Table 1). After
PCR amplification, DNA fragments were electrophoresed
in 1X MDE gel (FMC BioProducts, USA), and visualized
with silver staining. All amplicons not showing SSCP var-
iants with this method were electrophoresed in a 12%
polyacrylamide gel in 1X TBE buffer and run at room tem-
perature at a constant 25 mA for 14–16 h, with and with-
out 5% glycerol. All SSCP variants were investigated by
direct sequencing using the PRISM Dye Terminator Cycle
Sequencing kit and an ABI 310 automated sequencer
(Applied Biosystems) according to the manufacturer's
instructions.
Abbreviations
SSCP, single-strand conformational polymorphism; CH2,
collagen-like domain at the amino-terminus; MI, myocar-
dial infarction, CAD, coronary artery disease; SNP, single
nucleotide polymorphism.
Authors' contributions
The studies were designed by FS and MGB. All subjects
data were obtained by AB, FB, MF and the database organ-
ization was carried out by SR and MF. Experimental data
was obtained by FS and EF. Data analyses were performed
by FS and MGB. The paper was written by FS and MGB
and all authors read and approved the final manuscript.
Acknowledgements
Financial support to this work was provided by the Faculty of Medicine 
(grant n. C26F022871) of the University of Rome "La Sapienza" and by the 
Ministry of Health (grant RF2003) all to M.G. Baroni.
References
1. Abe J, Berk BC: Reactive oxygen species as mediators of signal
transduction in cardiovascular disease.  Trends Cardiovasc Med
1998, 8:59-64.
2. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E,
Milia E, Martin-Padura I, Raker VA, Maccarana M, Petronilli V, Minucci
S, Bernardi P, Lanfrancone L, Pelicci PG: A p53-p66shc signaling
pathway controls intracellular redox status, levels of oxida-
tion-damaged DNA and oxidative stress-induced apoptosis.
Oncogene 2002, 21:3872-3878.
3. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lan-
francone L, Pelicci PG: The p66shc adaptor protein controls oxi-
dative stress response and life span in mammals.  Nature 1999,
402:309-313.
4. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Fuga G,
Pawson T, Di Fiore PP, Lanfrancone L, Pelicci PG: Opposite effects
of the p52shc/p46shc and p66shc splicing isoforms on the
EGF receptor MAP kinase-fos signaling pathway.  EMBO J
1997, 16:706-716.
5. Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo
A, Biglioli P, Giorgio M, Martin-Padura I, Pelicci PG, Capogrossi MC:
p66ShcA modulates tissue response to hindlimb ischemia.
Circulation 2004, 109:2917-2923.
6. Napoli C, Martin-Padura I, de Nigris F, Giorgio M, Mansueto G,
Somma P, Condorelli M, Sica G, De Rosa G, Pelicci PG: Deletion of
the p66Shc longevity gene reduces systemic and tissue oxida-
tive stress, vascular cell apoptosis, and early atherogenesis in
mice fed a high-fat diet.  Proc Natl Acad Sci 2003, 100:2112-2116.
7. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G,
Nicoletti I, Grignani F, Pawson T, Pelicci PG: A novel transforming
protein (SHC) with an SH2 domain is implicated in
mitogenic signal transduction.  Cell 1992, 70:93-104.
8. Ventura A, Luzi L, Pacini S, Baldari CT, Pelicci PG: The p66Shc lon-
gevity gene is silenced through epigenetic modifications of
an alternative promoter.  J Biol Chem 2002, 277:22370-22376.
9. Graiani G, Lagrasta C, Migliaccio E, Spillmann F, Meloni M, Madeddu
P, Quaini F, Padura IM, Lanfrancone L, Pelicci P, Emanueli C: Genetic
deletion of the p66Shc adaptor protein protects from angi-
otensin II-induced myocardial damage.  Hypertension 2005,
46:433-440.
10. Francia P, delli Gatti C, Bachschmid M, Martin-Padura I, Savoia C,
Migliaccio E, Pelicci PG, Schiavoni M, Luscher TF, Volpe M, Cosentino
F:  Deletion of p66shc gene protects against age-related
endothelial dysfunction.  Circulation 2004, 110:2889-95.
11. Rissanen AM: Familial occurrence of coronary artery disease:
effect of age at diagnosis.  Am J Cardiol 1979, 44:60-66.
12. Marenberg ME, Risch N, Berkman LF, Floderus B, De Faire U:
Genetic susceptibility to death from coronary heart disease
in a study of twins.  N Engl J Med 1994, 330:1041-1046.
13. Mooijaart SP, van Heemst D, Schreuder J, van Gerwen S, Beekman M,
Brandt BW, Eline lagboom P, Westendorp RG, 'Long Life' Study
Group: Variation in the SHC1 gene and longevity in humans.
Exp Gerontol 2004, 39:263-268.
14. Almind K, Ahlgren MG, Hansen T, Urhammer SA, Clausen JO, Peder-
sen O: Discovery of a Met300Val variant in Shc and studies of
its relationship to birth weight and length, impaired insulin
secretion, insulin resistance, and type 2 diabetes mellitus.  J
Clin Endocrinol Metab 1999, 84:2241-2244.
15. Rea IM, McKeown PP, McMaster D, Young IS, Patterson C, Savage MJ,
Belton C, Marchegiani F, Olivieri F, Bonafe M, Franceschi C: Paraox-
onase polymorphisms PON1 192 and 55 and longevity in Ital-
ian centenarians and Irish nonagenarians. A pooled analysis.
Exp Gerontol 2004, 39:629-635.
16. Lio D, Candore G, Crivello A, Scola L, Colonna-Romano G, Cavallone
L, Hoffmann E, Caruso M, Licastro F, Caldarera CM, Branzi A, Franc-
eschi C, Caruso C: Opposite effects of interleukin 10 common
gene polymorphisms in cardiovascular diseases and in suc-
cessful ageing: genetic background of male centenarians is
protective against coronary heart disease.  J Med Genet 2004,
41:790-794.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genetics 2006, 7:14 http://www.biomedcentral.com/1471-2156/7/14
Page 6 of 6
(page number not for citation purposes)
17. Terry DF, McCormick M, Andersen S, Pennington J, Schoenhofen E,
Palaima E, Bausero M, Ogawa K, Perls TT, Asea A: Cardiovascular
disease delay in centenarian offspring: role of heat shock pro-
teins.  Ann N Y Acad Sci 2004, 1019:502-505.
18. Rose GA, Blackburn H: Cardiovascular Survey Methods. No 56 1st edi-
tion. Geneva (Switzerland): World Health Organization; 1968. 
19. Sentinelli F, Lovari S, Vitale M, Giorgi G, Di Mario U, Baroni MG: A
simple method for non-radioactive PCR-SSCP using MDE
gel solution and a midi gel format: application for the detec-
tion of variants in the GLUT1 and CTLA-4 genes.  J Biotechnol
2000, 78:201-204.